Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver G Ottmann

Showing results (81-90 of 102) with videos related to

Pageof 11
Sort By:
Blood|June 16, 2010
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cellsRuriko Tanaka, Matthew S Squires, Shinya Kimura, et al.
Leukemia & Lymphoma|February 8, 2025
Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemiaFabian Lang, Andreas Voss, Guido Kobbe, et al.
Leukemia Research|June 11, 2013
A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignanciesCarlos Graux, Anne Sonet, Johan Maertens, et al.
Blood|April 9, 2005
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)Barbara Wassmann, Heike Pfeifer, Michael Stadler, et al.
Blood|October 25, 2003
Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinibBarbara Wassmann, Heike Pfeifer, Urban J Scheuring, et al.
Cancer Letters|September 6, 2011
Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patientsRuriko Tanaka, Shinya Kimura, Eishi Ashihara, et al.
The New England Journal of Medicine|June 16, 2006
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALLHagop Kantarjian, Francis Giles, Lydia Wunderle, et al.
Haematologica|July 4, 2007
An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCRMartin C Müller, Guiseppe Saglio, Feng Lin, et al.
Blood|July 10, 2014
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapyHartmut Döhner, Michael Lübbert, Walter Fiedler, et al.
Blood|July 5, 2003
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemiaWalter Fiedler, Rolf Mesters, Heike Tinnefeld, et al.
Pageof 11

Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
Blood|June 16, 2010
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cellsRuriko Tanaka, Matthew S Squires, Shinya Kimura, et al.
Leukemia & Lymphoma|February 8, 2025
Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemiaFabian Lang, Andreas Voss, Guido Kobbe, et al.
Leukemia Research|June 11, 2013
A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignanciesCarlos Graux, Anne Sonet, Johan Maertens, et al.
Blood|April 9, 2005
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)Barbara Wassmann, Heike Pfeifer, Michael Stadler, et al.
Blood|October 25, 2003
Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinibBarbara Wassmann, Heike Pfeifer, Urban J Scheuring, et al.
Cancer Letters|September 6, 2011
Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patientsRuriko Tanaka, Shinya Kimura, Eishi Ashihara, et al.
The New England Journal of Medicine|June 16, 2006
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALLHagop Kantarjian, Francis Giles, Lydia Wunderle, et al.
Haematologica|July 4, 2007
An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCRMartin C Müller, Guiseppe Saglio, Feng Lin, et al.
Blood|July 10, 2014
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapyHartmut Döhner, Michael Lübbert, Walter Fiedler, et al.
Blood|July 5, 2003
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemiaWalter Fiedler, Rolf Mesters, Heike Tinnefeld, et al.
Pageof 11